Results 171 to 180 of about 3,808,290 (359)

ETV4 Promotes Colorectal Cancer Progression by Reprogramming Asparagine Metabolism to Remodel the Stromal Microenvironment

open access: yesAdvanced Science, EarlyView.
ETV4 coordinates a dual transcriptional program by upregulating MET and asparagine synthetase (ASNS). The resulting asparagine (Asn) secretion acts as a metabolic signal, reprogramming hepatic stellate cells (HSCs) and primary cancer‐associated fibroblasts (CAFs) toward an inflammatory phenotype. These activated stromal cells release HGF to sustain the
Dujiang Fu   +14 more
wiley   +1 more source

Bone Marrow Reticulin Content In Acute Leukemia

open access: yesمجلة كلية الطب, 2006
Background: Increase in marrow reticulin has long been recognized in primary myelofibrosis, but little was known about the reticulin structure of leukemic marrows, there has been a tendency to accept an increase in marrow reticulin as evidence of ...
Eman Sadiq Jalal
doaj  

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

open access: yesNew England Journal of Medicine, 2017
H. Kantarjian   +25 more
semanticscholar   +1 more source

β‐Adrenergic Signaling Promotes Anti‐Tumor Immunity in TP53‐mutant Oral Squamous Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
β‐adrenergic stimulation enhances anti‐tumor immunity in TP53‐deficient oral squamous cell carcinoma by inducing tumor‐derived secretion of CXCL10, which attracts and activates cytotoxic CD8+ T cells. The findings demonstrate that β‐adrenergic signaling alters tumor–immune interactions via CXCL10‐mediated paracrine activation, revealing a neuro‐immune ...
Frederico O. Gleber‐Netto   +20 more
wiley   +1 more source

Mitochondrial CircRNA CircMT‐RNR2 Safeguards Antioxidant Defense to Support Fibroblast Functions in Wound Repair

open access: yesAdvanced Science, EarlyView.
CircMT‐RNR2 promotes wound healing by enhancing fibroblast proliferation, migration, contraction, and extracellular matrix (ECM) production. It sustains mitochondrial redox balance by stabilizing the antioxidant protein PRDX3, thereby reducing ROS‐induced damage. In diabetic foot ulcers, hypoxia, hyperglycemia, and reduced FGF2 and EGF expression lower
Guanglin Niu   +13 more
wiley   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

open access: yesAdvanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu   +11 more
wiley   +1 more source

Depletion of the RNA‐Editing Enzyme ADAR1 Invigorates the Antitumor Immunity of NK Cells

open access: yesAdvanced Science, EarlyView.
ADAR1 is upregulated in NK cells from melanoma patients, impairing their function. Its loss enhances NK cell tumor infiltration and cytotoxicity in vitro and in vivo. Mechanistically, ADAR1 deficiency destabilizes CD38 mRNA to reduce its expression, thereby increasing NK cell mobility and killing, which nominates it as a therapeutic target for NK cell ...
Shuhan Chen   +11 more
wiley   +1 more source

Asciminib for relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia

open access: yesBlood Advances
Mathilde Chanut   +28 more
doaj   +1 more source

Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides

open access: yesAdvanced Science, EarlyView.
Single‐cell RNA analyses of paired lesions from CD30+ mycosis fungoides patients demonstrate that brentuximab vedotin (BV) induces immunogenic cell death in both CD30+ and CD30− malignant T cells. BV also targets regulatory T cells and remodels tumor microenvironment, while resistance is driven by impaired IFN responses, drug efflux, and BCL2 ...
Yi Jiang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy